Literature DB >> 22157705

FGF23 beyond mineral metabolism: a bridge to cardiovascular disease.

Tobias E Larsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22157705      PMCID： PMC3255380          DOI： 10.2215/CJN.10711011

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  33 in total

1.  The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

Authors:  Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

2.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

Authors:  Vardit Lavi-Moshayoff; Gilad Wasserman; Tomer Meir; Justin Silver; Tally Naveh-Many
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-04

3.  Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.

Authors:  Tamara Isakova; Huiliang Xie; Allison Barchi-Chung; Gabriela Vargas; Nicole Sowden; Jessica Houston; Patricia Wahl; Andrew Lundquist; Michael Epstein; Kelsey Smith; Gabriel Contreras; Luis Ortega; Oliver Lenz; Patricia Briones; Phyllis Egbert; T Alp Ikizler; Harald Jueppner; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

4.  Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.

Authors:  Hisashi Hasegawa; Nobuo Nagano; Itaru Urakawa; Yuji Yamazaki; Kousuke Iijima; Toshiro Fujita; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shimada
Journal:  Kidney Int       Date:  2010-09-15       Impact factor: 10.612

5.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

6.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

7.  FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

Authors:  Takashi Shimada; Itaru Urakawa; Yuji Yamazaki; Hisashi Hasegawa; Rieko Hino; Takashi Yoneya; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Biochem Biophys Res Commun       Date:  2004-02-06       Impact factor: 3.575

8.  Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

Authors:  Shiguang Liu; Rong Guo; Leigh G Simpson; Zhou-Sheng Xiao; Charles E Burnham; L Darryl Quarles
Journal:  J Biol Chem       Date:  2003-07-21       Impact factor: 5.157

9.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Authors:  Tobias Larsson; Ulf Nisbeth; Osten Ljunggren; Harald Jüppner; Kenneth B Jonsson
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808
View more
  8 in total

1.  Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis.

Authors:  Amir Ahmad Nassiri; Monir Sadat Hakemi; Reza Safar-Pour; Ali Ahmadi; Maryam Tohidi; Babak Sharif Kashani; Fatemeh Esfehani; Soudabeh Alatab
Journal:  J Transl Int Med       Date:  2016-09-23

2.  Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis.

Authors:  Juan C Ramirez-Sandoval; Ivan Casanova; Alejandro Villar; F Enrique Gomez; Cristino Cruz; Ricardo Correa-Rotter
Journal:  Perit Dial Int       Date:  2015-08-20       Impact factor: 1.756

3.  Markers of Bone Mineral Metabolism and Cardiac Structure and Function in Perinatally HIV-Infected and HIV-Exposed but Uninfected Children and Adolescents.

Authors:  Renee Margossian; Paige L Williams; Wendy Yu; Denise L Jacobson; Mitchell E Geffner; Linda A DiMeglio; Russell B Van Dyke; Stephen A Spector; Gertrud U Schuster; Charles B Stephensen; Tracie L Miller; Steven E Lipshultz
Journal:  J Acquir Immune Defic Syndr       Date:  2019-06-01       Impact factor: 3.731

4.  Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis.

Authors:  Shuhong Bi; Yaoxian Liang; Litao Cheng; Yue Wang; Tao Wang; Qinfeng Han; Aihua Zhang
Journal:  Int Urol Nephrol       Date:  2017-04-28       Impact factor: 2.370

5.  Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study.

Authors:  Romina di Giuseppe; Tilman Kühn; Frank Hirche; Brian Buijsse; Jutta Dierkes; Andreas Fritsche; Rudolf Kaaks; Heiner Boeing; Gabriele I Stangl; Cornelia Weikert
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

6.  Upregulation of Oxidative Stress Related Genes in a Chronic Kidney Disease Attributed to Specific Geographical Locations of Sri Lanka.

Authors:  Saravanabavan Sayanthooran; Dhammika N Magana-Arachchi; Lishanthe Gunerathne; Tilak D J Abeysekera; Suneth S Sooriyapathirana
Journal:  Biomed Res Int       Date:  2016-11-16       Impact factor: 3.411

7.  A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

Authors:  Adrian Covic; Jutta Passlick-Deetjen; Miroslaw Kroczak; Beatrix Büschges-Seraphin; Adrian Ghenu; Pedro Ponce; Barbara Marzell; Angel L M de Francisco
Journal:  Nephrol Dial Transplant       Date:  2013-06-19       Impact factor: 5.992

8.  Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study.

Authors:  Robin Haring; Danielle Enserro; Vanessa Xanthakis; Gary F Mitchell; Emelia J Benjamin; Naomi M Hamburg; Lisa Sullivan; Matthias Nauck; Henri Wallaschofski; Ramachandran S Vasan
Journal:  J Am Heart Assoc       Date:  2016-07-06       Impact factor: 5.501
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.